Gabapentin Should Not Be Used in COPD Patients
Gabapentin use in patients with COPD is associated with significantly increased risk of severe exacerbations and should be avoided unless absolutely necessary, with extreme caution if prescribed.
Evidence Against Gabapentin Use in COPD
Increased Risk of Severe Exacerbations
The most recent and highest quality evidence demonstrates clear harm:
Gabapentin use increases the risk of severe COPD exacerbations requiring hospitalization by 39% overall (HR 1.39,95% CI 1.29-1.50) 1
This increased risk is consistent across all indications:
A 2025 UK study confirmed these findings with 43% increased risk of severe exacerbation (HR 1.43,95% CI 1.35-1.52) in nearly 30,000 gabapentinoid users 2
Compared to other CNS-active medications (TCAs and SNRIs) used for the same indications, gabapentinoids showed 18-21% higher risk of exacerbations requiring systemic corticosteroids 3
Mechanism of Respiratory Harm
Gabapentin causes CNS depression including somnolence and sedation, which can impair respiratory drive 4
The FDA label explicitly warns about respiratory depression risk, particularly in patients with respiratory risk factors 4
Somnolence occurs in 21% of gabapentin-treated patients (vs 5% placebo), and dizziness in 28% (vs 8% placebo) 4
When Gabapentin Might Be Considered (With Extreme Caution)
Limited Exception: Refractory Chronic Cough in Interstitial Lung Disease
The only respiratory guideline mentioning gabapentin use is for refractory chronic cough in interstitial lung disease (ILD), not COPD:
The CHEST guideline suggests gabapentin trials for ILD patients with refractory chronic cough when other treatments have failed 5
This is an ungraded consensus-based statement for a different disease entity 5
For unexplained chronic cough (not COPD-related), gabapentin is suggested with mandatory risk-benefit discussion and reassessment at 6 months 6
Critical Caveats if Prescribing
If gabapentin must be used in a COPD patient despite the evidence of harm:
Start at 300 mg once daily, titrate slowly to maximum 1,800 mg/day in divided doses 4
Discuss potential side effects and respiratory risks explicitly before initiation 6
Reassess risk-benefit profile at 1 week, then monthly before continuing 6
Adjust dose for renal impairment (common in COPD patients): reduce to 200-700 mg/day for CrCl 15-29 mL/min 4
Monitor closely for increased somnolence, dizziness, and respiratory symptoms 4
Avoid concurrent use with opioids or other CNS depressants due to synergistic respiratory depression 4
Standard COPD Management Does Not Include Gabapentin
Multiple COPD guidelines make no mention of gabapentin as a treatment option:
Standard pharmacotherapy includes bronchodilators (LABA, LAMA), inhaled corticosteroids, and PDE4 inhibitors for appropriate patients 7, 8, 9
No anti-inflammatory drugs beyond ICS have a role in COPD management 10
Neuromodulators like gabapentin are not part of evidence-based COPD treatment algorithms 7, 8, 9
Common Pitfall to Avoid
Do not prescribe gabapentin for neuropathic pain or other indications in COPD patients without considering safer alternatives first (such as TCAs or SNRIs, which show lower exacerbation risk) 3. The convenience of gabapentin prescribing must be weighed against the substantial increased risk of life-threatening COPD exacerbations requiring hospitalization 2, 1.